Now, they run Cambridge, Massachusetts-based mRNA company Strand Therapeutics. The company announced a $52 million in a Series A round in June.

Lipids formulated with a bioreducible linker form the wall of nanoparticles encapsulating the mRNA of Cas9 plus sgRNA. Upon entering the cell, in vitro or in vivo, the linkers are broken and the ...

Strand’s therapy uses mRNA to make an inflammatory protein called interleukin-12, or IL-12, that causes immune cells to spring into action and unleash a cascade of events that kill cancer cells ...

What's the difference between mRNA and pre-mRNA? It's all about splicing of introns. See how one RNA sequence can exist in nearly 40,000 different forms.

Strand Therapeutics, a Massachusetts Institute of Technology (MIT) spinout, has developed a new class of advanced mRNA molecules for more targeted and powerful treatments for cancer. The new class of ...

Strand will present preclinical data from its lead programmable mRNA candidate STX-001, a multi-modal synthetic self-replicating mRNA technology that delivers a prolonged and locally-acting IL-12 ...

The bound guide strand is anchored at both of its ends, with the solvent-exposed Watson–Crick edges of stacked bases 2 to 6 positioned for nucleation with the mRNA target, whereas two critically ...